Document:

10.2 Form of Employee Change in Control Agreement

                           FIRST AMENDED AND RESTATED
                      EMPLOYEE CHANGE IN CONTROL AGREEMENT
                 NOT TO BE CONSTRUED AS AN EMPLOYMENT AGREEMENT

                      THE FIRST NATIONAL BANK OF LITCHFIELD
                     FIRST LITCHFIELD FINANCIAL CORPORATION
                                 13 North Street
                             Litchfield, Connecticut

         WHEREAS,  The First  National Bank of  Litchfield  (the "Bank") and its
parent  bank  holding  company,  First  Litchfield  Financial  Corporation  (the
"Holding   Company"),   wish  to  continue  to  employ  (insert  employee  name)
("Employee"), [address], as [insert employee's title] of the Bank.

         WHEREAS,  the Bank  and the  Holding  Company  expect  that  Employee's
contributions  and knowledge will continue to be of  significant  benefit to the
future growth and success of the Bank;

         WHEREAS,  the Boards of Directors  of the Bank and the Holding  Company
recognize  that a change in control of the Bank and/or the  Holding  Company may
occur and that the threat of such change in control may create  uncertainty  and
may  result  in the  distraction  or  departure  of long term  personnel  to the
detriment of the Bank and Holding Company and their stockholders;

         WHEREAS,  the Boards have determined that  appropriate  steps should be
taken to reinforce and  encourage  the continued  dedication of employees of the
Bank  including  Employee,  to their  assigned  duties in the face of  potential
circumstances involving the possibility of such a change in control; and

         WHEREAS, the Bank, the Holding Company and the Employee have previously
entered an Employee Change in Control  Agreement dated ___________ __, 2006 wish
to enter this First Amended and Restated  Employee  Change in Control  Agreement
(this  "Agreement") to reflect changes  required by Section 409A of the Internal
Revenue Code;

         NOW  THEREFORE,  in addition  to one dollar  ($1.00) and other good and
valuable  consideration  paid by the Bank to  Employee  and in  order to  induce
Employee  to  continue  employment  with  the Bank and to  continue  to  perform
Employee's  duties in a manner which is in the best  interests of the Bank,  the
Bank and Holding Company hereby agree to provide  Employee with certain benefits
in the  event  his/her  employment  with the Bank  terminates  or is  reassigned
subsequent  to a Change in Control  (as  defined in Section 2 hereof)  under the
circumstances described below.

         1. Term of Agreement;  Employment  Status.  This  Agreement  shall take
effect  when  signed by all  parties  and shall  remain in full force and effect
until  June 1,  2010.  All  employees  of Bank and  Holding  Company,  including
Employee, are employees at will. The terms of this Agreement,  therefore, do not
and are not  intended to create  either an express  and/or  implied  contract of
employment  with the Bank  and/or the Holding  Company.  This  Agreement  simply

                                       12
<PAGE>

provides  certain  potential  benefits to Employee in the event that a Change in
Control, as hereinafter defined, occurs prior to June 1, 2010.

         2. Change in Control.  No benefits  shall be payable  hereunder  unless
prior to June 1,  2010,  there  shall have been a Change in Control as set forth
below, and thereafter within six (6) months of such Change in Control Employee's
employment  with the  Bank  and/or  its  successor  terminates  or  Employee  is
reassigned in accordance with Section 3, below.  For purposes of this Agreement,
a "Change in Control" shall mean a change in the ownership or effective  control
of the Bank or the Holding Company, or in the ownership of a substantial portion
of the assets of the Bank or the Company and shall occur upon the  occurrence of
any of the following:

                  (a) The date  that any one  person,  or more  than one  person
         acting as a group,  acquires  ownership  of stock that,  together  with
         stock previously acquired,  constitutes more than 50% of the total fair
         market value or total voting power of the stock of the Bank (other than
         by the Holding Company) or the Holding Company;

                  (b) The date  that any one  person,  or more  than one  person
         acting as a group,  acquires (or has acquired in the preceding 12-month
         period)  ownership of stock  possessing 50% or more of the total voting
         power of the Bank (other  than by the  Holding  Company) or the Holding
         Company;

                  (c) The  date  that a  majority  of  members  of the  Board of
         Directors  of the Bank or the Holding  Company is  replaced  during any
         12-month  period by  directors  whose  appointment  or election was not
         endorsed  by a  majority  of  the  members  of  the  Board  before  the
         appointment or election; or

                  (d) The date  that any one  person,  or more  than one  person
         acting as a group, acquires ownership (or has acquired in the preceding
         12-month  period) of assets from the of the Bank or the Holding Company
         that have a total gross fair  market  value of 50% or more of the total
         gross fair market  value of all of the assets  immediately  before such
         acquisition  or  acquisitions.  Gross fair market value of assets means
         the fair value of the assets without regard to any liability associated
         with such assets.

With respect to the above  description of a "Change in Control," all terms shall
have the meaning set forth in defined in Section  409A of the  Internal  Revenue
Code and Treasury Reg. ss.409A-3(i)(5) thereunder, as amended from time to time.

         3.  Termination  Following  Change  in  Control.  If any of the  events
described  in  Section 2 hereof  constituting  a Change in  Control  shall  have
occurred,  Employee  shall be entitled to the  benefits  provided for in Section
4(a) hereof upon the  Termination of Employment or  Reassignment  (as defined in
this  Section  3) of  Employee's  employment  duties or  responsibilities  as an
employee of the Bank and/or its  successor as provided in this Section 3, within
six (6) months  after such  event,  unless such  Termination  of  Employment  or
Reassignment  is  :  (i)  by  any  regulatory   authority  (acting  with  proper
jurisdiction);  or (ii) by the  Board of  Directors  of the Bank or the  Holding
Company  for  cause;  or  (iii)  because  of  Employee's  death,  retirement  or
disability.  Such benefits  shall be reduced by the amount of any severance paid
to Employee by the Bank or its successor.

                                       13
<PAGE>

         (a) Retirement; Disability.

                  (i)  Termination of Employment by the Bank based on retirement
shall mean the  mandatory  termination  of  employment  in  accordance  with the
retirement policy of the Bank, including (at Employee's sole election and as set
forth  in  writing)  early  retirement,  generally  applicable  to its  salaried
employees or in accordance  with any  retirement  arrangement  established  with
Employee's consent with respect to Employee.

                  (ii) Termination of Employment by the Bank based on disability
shall  mean the  Employee  (i) is unable to  engage in any  substantial  gainful
activity by reason of any medically  determinable  physical or mental impairment
which  can be  expected  to  result  in death or can be  expected  to last for a
continuous  period of not less than twelve  (12)  months;  or (ii) is  receiving
income replacement benefits for a period of not less than three (3) months under
an accident and health plan  covering the employees of the Bank by reason of any
medically  determinable  physical or mental  impairment which can be expected to
result in death or last for a continuous  period of at least twelve (12) months.
The Employee  shall be deemed  disabled if determined to be totally  disabled by
the Social Security Administration.

         (b)  Notice  of  Termination.  The Bank  agrees  that in the event of a
Termination  of  Employment  it will  promptly  furnish  Employee with a written
Notice  of  Termination.   Any  purported  Reassignment  of  Employee  shall  be
communicated  by written Notice of Termination to the Bank. For purposes of this
Agreement, a "Notice of Termination" shall mean a notice which shall include the
specific termination provision in this Agreement relied upon and shall set forth
in reasonable detail the facts and circumstances  claimed to provide a basis for
termination of Employee's employment under the provision so indicated.

         (c) Date of Termination.  "Date of Termination"  shall mean the date on
which a Notice of Termination  is given;  provided that, if within five (5) days
after any Notice of  Termination  is given,  the party  receiving such Notice of
Termination  notifies  the other  party  that a dispute  exists  concerning  the
termination,  the Date of Termination  shall be the date on which the dispute is
finally  determined,  either by mutual  written  agreement of the parties,  by a
binding and final arbitration award or by a final judgment, order or decree of a
court of competent  jurisdiction  (the time for appeal  therefrom having expired
and no appeal having been perfected).

         (d) Reassignment.  "Reassignment" shall mean a reduction in base salary
or an  involuntary  reassignment  of  Employee's  duties,  responsibilities,  or
benefits  materially  inconsistent with those of Employee prior to the Change in
Control  or  the  involuntary   relocation  of  Employee's  primary  duties  and
responsibilities  to an office or  location  greater  than fifty (50) miles from
Litchfield,  Connecticut  or action which results in a significant  worsening of
the Employee's  work  conditions  (including,  but not limited to, a significant
change  in  employment   duties,   responsibilities,   required  work  hours  or
otherwise).

                                       14
<PAGE>

         4. Compensation Upon Termination or Reassignment.

         (a) If, within six (6) months after a Change in Control,  as defined in
Section 2 hereof,  shall have occurred,  there is a Termination of Employment or
Reassignment  of  Employee  as defined in Section 3 (except by an agency  acting
with proper jurisdiction, or by a board of directors for cause or as a result of
death,  retirement or disability),  then the Bank and/or its successor shall pay
Employee  (i) if  Employee  is a  "Specified  Employee"  as  defined  in Section
409A(a)(2)(B)(i)  of the  Internal  Revenue  Code,  on the date which is six (6)
months  after the Date of  Termination  or (ii) if  Employee  is not a Specified
Employee as defined,  within five (5) days after the Date of Termination,  or in
each case as soon thereafter as is practicable, an amount equal to the sum of:

                  (i) Six (6) months of  Employee's  annual  compensation  based
upon the most recent aggregate base salary paid to Employee in the six (6) month
period  immediately  preceding his/her  termination or reassignment less amounts
previously paid to Employee from the date of Change in Control; plus

                  (ii) Reasonable  legal fees and expenses  incurred by Employee
as a result of such  Termination  of Employment or  Reassignment  (including all
such fees and  expenses,  if any,  incurred in  contesting or disputing any such
Termination of Employment or Reassignment or in seeking to obtain or enforce any
right or benefit provided for by this Agreement).

         (b)  Employee  shall not be  required  to  mitigate  the  amount of any
payment provided for in this Section 4 by seeking other employment or otherwise,
nor shall the amount of any payment provided for in this Section 4 be reduced by
any  compensation  earned by  Employee  as the result of  employment  by another
employer after the Date of Termination , or otherwise.

         (c) It is the  intention  of the  parties  to  this  Agreement  that no
payments by the Bank to or for Employee's  benefit under this Agreement shall be
non-deductible  to the Bank by reason of the  operation  of Section  280G of the
Internal Revenue Code. Accordingly,  notwithstanding any other provision hereof,
if by reason of the operation of said Section 280G of the Internal Revenue Code,
any such  payments  exceed the amount  which can be  deducted  by the Bank,  the
amount of such payments shall be reduced to the maximum which can be deducted by
the Bank.  To the extent  that  payments  in excess of the  amount  which can be
deducted by the Bank have been made to and for Employee's benefit, they shall be
refunded with interest at the applicable  rate provided under Section 1274(d) of
the  Internal  Revenue  Code,  or at such other rate as may be required in order
that no such  payment  to or for  Employee's  benefit  shall  be  non-deductible
pursuant  to Section  280G of the  Internal  Revenue  Code.  Any  payments  made
hereunder  which are not deductible by the Bank as a result of losses which have
been carried  forward by the Bank for Federal tax purposes shall not be deemed a
non-deductible amount for purposes of this Section 4(c).

         5.  Continuation  of  Insurance  Benefits.  Notwithstanding  any  other
provision in this Agreement to the contrary, the Bank and/or its successor shall
maintain in full force and effect for Employee's  continued benefit, for the six
(6)  month  period  beginning  upon a Change  in  Control,  all life  insurance,
medical,  health and  accident  and  disability  policies,  plans,  programs  or
arrangements which were in effect immediately prior to the Change in Control.

                                       15
<PAGE>

         6. Successors; Binding Agreement.

         (a) The  Bank  and the  Holding  Company  will  require  any  successor
(whether direct or indirect, by purchase, merger, consolidation,  acquisition of
assets or assumption of liabilities or otherwise) to all or substantially all of
the business and/or assets and/or  deposits of the Bank or the Holding  Company,
by  agreement,  to expressly  assume and agree to perform this  Agreement in the
same manner and to the same extent that the Bank would be required to perform it
if no such  succession  had taken  place.  Failure  of the Bank  and/or  Holding
Company  to  obtain  such  agreement  prior  to the  effectiveness  of any  such
succession  shall be a breach of this  Agreement and shall  entitle  Employee to
compensation  from the Bank in the same amount and on the same terms as he would
be entitled to hereunder if Employee's  employment had terminated as a result of
a Termination  of Employment or  Reassignment,  as provided in Section 3 hereof,
after a  Change  in  Control,  except  that for  purposes  of  implementing  the
foregoing,  the date on which any such  succession  becomes  effective  shall be
deemed the Date of Termination. As used in this Agreement, "Bank" shall mean the
Bank as  hereinbefore  defined and any successor to the business,  assets and/or
deposits as aforesaid which executes and delivers the agreement  provided for in
this Section 6 or which otherwise  becomes bound by all the terms and provisions
of this Agreement by operation of law.

         (b) This Agreement  shall inure to the benefit of and be enforceable by
Employee's  personal  or  legal  representatives,   executors,   administrators,
successors,  heirs, distributees,  devisees and legatees. If Employee should die
after any rights to receive the  amounts  contemplated  hereby  have  accrued to
Employee  but before  such  amounts  have been paid,  all such  amounts,  unless
otherwise  provided  herein,  shall be paid in accordance with the terms of this
Agreement to Employee's  devisee,  legatee or other  designee or, if there be no
such designee, to Employee's estate.

         7. Notices. All notices and other  communications  provided for in this
Agreement  shall be in writing  and shall be deemed to have been duly given when
delivered or mailed by United States registered mail, return receipt  requested,
postage  prepaid,  addressed to the respective  addresses set forth on the first
page of this  Agreement,  provided  that all notices to the Bank and the Holding
Company  shall be  directed  to the  attention  of the Board  with a copy to the
Chairman  of the Board of the Bank and the  Chairman of the Board of the Holding
Company or to such other address as either party may have furnished to the other
in writing in accordance herewith, except that notice of change of address shall
be effective only upon receipt.

         8.  Miscellaneous.  No  provision  of this  Agreement  may be modified,
waived or discharged unless such waiver,  modification or discharge is agreed to
in writing and signed by Employee and such other officer as may be  specifically
designated by the Board of the Bank or the Holding Company.  No waiver by either
party  hereto at any time of any breach by the other or  failure to comply  with
any condition or provision of this Agreement to be performed by such other party
shall be deemed a waiver of similar or  dissimilar  provisions  or conditions at
the same or at any prior or subsequent  time. No agreements or  representations,
oral or otherwise, express or implied, with respect to the subject matter hereof
have  been  made by  either  party  which  are not  expressly  set forth in this
Agreement.  The validity,  interpretation,  construction and performance of this
Agreement  shall be governed by the laws of the State of Connecticut  and of the
United States of America.

                                       16
<PAGE>

         9.  Validity.  The invalidity or  unenforceability  of any provision of
this  Agreement  shall not affect the  validity or  enforceability  of any other
provision of this Agreement, which shall remain in full force and effect.

         10.   Administration  and  Interpretation.   This  Agreement  shall  be
administered  in a  manner,  and all  provisions  of  this  Agreement  shall  be
interpreted to be, compliant with the provisions of Section 409A of the Internal
Revenue  Code,  and  regulations  and rulings  issued  thereunder,  so as not to
subject  the  benefits  accruing  hereunder  to  taxation  pursuant  to  Section
409A(a)(1) of the Internal Revenue Code.

         11.   Counterparts.   This   Agreement   may  be  executed  in  several
counterparts,  each of which shall be deemed to be an original  but all of which
together will constitute one and the same instrument.

         12.  Arbitration.  Any  dispute  or  controversy  arising  under  or in
connection  with this Agreement  shall be settled  exclusively by arbitration in
Litchfield,   Connecticut,   in  accordance  with  the  rules  of  the  American
Arbitration Association then in effect. Notwithstanding the pendency of any such
dispute or controversy,  the Bank will pay Employee  promptly an amount equal to
Employee's full scheduled  compensation in effect when the notice giving rise to
the dispute was given  (including,  but not limited to, base salary) and provide
Employee with all scheduled compensation,  benefits and insurance plans in which
he was participating when the notice giving rise to the dispute was given, until
the dispute is finally  resolved in  accordance  with Section 3 hereof.  Amounts
paid under this  Section 12 are in addition to all other  amounts due under this
Agreement and shall not be offset  against or reduce any other amounts due under
this Agreement.  Judgment may be entered on the arbitrator's  award in any court
having jurisdiction;  provided, however, that Employee shall be entitled to seek
specific  performance  of  Employee's  right  to  be  paid  until  the  Date  of
Termination  during the pendency of any dispute or controversy  arising under or
in connection with this Agreement.

         13. Entire  Agreement.  This Agreement  supersedes the prior  agreement
between the Bank,  the Holding  Company and the  Employee on the subject  matter
hereof dated May 26, 2006 and constitutes the entire agreement between the Bank,
the Holding  Company and the Executive on the subject matter  hereof.  No rights
are  granted  to the  Executive  by virtue of this  Agreement  other  than those
specifically set forth herein.

                           [Signatures on next page.]

                                       17
<PAGE>

         Agreed  to this  _______  day of  ______________,  2008,  by and  among
Employee, The First National Bank of Litchfield,  and First Litchfield Financial
Corporation.

                                        THE FIRST NATIONAL BANK OF LITCHFIELD

                                        By: _______________________________
                                                 [Name of Employee]
                                        Its:     President and CEO
                                                 Duly Authorized

                                        FIRST LITCHFIELD FINANCIAL CORPORATION

                                        By: _______________________________
                                                 [Name of President and CEO]
                                        Its:     President and CEO
                                                 Duly Authorized

                                        EMPLOYEE

                                        Signature: _________________________
                                        [Name]

                                       18
<PAGE>

STATE OF CONNECTICUT       )
                           ) ss. Litchfield
COUNTY OF LITCHFIELD       )

         On  this  the  _______  day  of  ___________,   2008,  before  me,  the
undersigned,  personally  appeared [Name of President and CEO], who acknowledged
himself to be the  President and CEO of THE FIRST  NATIONAL BANK OF  LITCHFIELD,
and FIRST LITCHFIELD FINANCIAL CORPORATION, and that he as such President, being
authorized so to do, executed the foregoing  instrument for the purposes therein
contained by signing his name.

                                     In Witness Whereof, I hereunto set my hand.

                                     ----------------------------
                                     Notary Public
                                     My Commission Expires: ____________________

STATE OF CONNECTICUT       )
                           ) ss. Litchfield
COUNTY OF LITCHFIELD       )

         On  this,  the  _______  day  of  ___________,  2008,  before  me,  the
undersigned  officer,  personally appeared [Name], known to me or satisfactorily
proven to be the person signing the foregoing  document,  and acknowledged  that
he/she executed the same for the purposes therein  contained as his/her free act
and deed.

                                     In Witness Whereof, I hereunto set my hand.

                                     ----------------------------
                                     Notary Public
                                     My Commission Expires: ____________________

                                       19-- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing

Exhibit 10.1

CONFIDENTIAL TREATMENT REQUEST

[ * ] Indicates information that has been omitted pursuant to a confidential treatment request and this information has been filed under separate cover with the Commission. 

Execution Copy

CONTRACT MANUFACTURE AGREEMENT

	BPL:	 	BIO PRODUCTS LABORATORY, a unit of the Authority (as defined below), having its principal place of business at Dagger Lane, Elstree, Herts, WD6 3BX, U.K.
	 	
	Client:	 		GAMMACAN LTD., whose principal place of business is 39 Jerusalem Street, Kiryat Ono, Israel 55423 an Israeli Corporation of company registration number 513546457.

This Agreement is made on the date when both parties have signed below subject to the Key Terms and the attached Schedules listed below which both BPL and Client undertake to observe in the performance of this
Agreement. 

	
Key Terms	
	 	
Agreement		 	 	
This Contract Manufacture Agreement including these Key Terms and all schedules and appendices attached hereto.		 
	 	
Authority		 	 	
Means NHS Blood and Transplant (NHSBT), a Special Health Authority in succession to the National Blood Authority of England established by United Kingdom Statutory Instruments (numbers 2529, 2531 and 2532 of 2005) and any authority created and acting in succession thereto.		 
	 	By-Products 	 	 	The following [ * ] by-products that are derived
	      from the manufacturing of Plasma: [ * ]	 
	 	
Client Materials		 	 	
[ * ]		 
	 	Commencement

Date:	 	 	The date of this Agreement.	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	
Donor Centres		 	 	
Those donor centres set out in Schedule 5.		 
	 	
Fees		 	 	
The Manufacturing Fee, the Service Fee and the Royalties.		 
	 	
Manufacturing

Fee		 	 	
The fees for the manufacturing of
the [ * ] as set out in Schedule 2 and any
fee for manufacturing [ * ] 
set forth in Schedule 2.		 
	 	
Manufacturing

Improvements	 	 	
Any improvement, enhancement or modification to the GAMMAPLEX Data (as defined in Appendix 1 of Schedule 6), patentable
or otherwise;	 
	 	
Net Revenues		 	 	
[ * ]		 
	 	
Net Sales		 	 	
“Net Sales” means [ * ].		 
	 	
Phase I/II

Batches	 	 	
[ * ] litre
batches of Plasma with a yield of between [ * ]
grams IVIG per litre of Plasma;

[ * ] litre batches of Plasma with a yield
of between [ * ] grams IVIG per litre of Plasma.	 
	 	
Phase III

Batches	 	 	
[ * ] litre batches of Plasma [ * ] with a yield of between [ * ] IVIG
per litre of Plasma.	 
	 	Plasma 	 	 	
 Vitiligo
plasma supplied by Client from the Donor Centres which complies with the approved
Plasma Specification. 	 
	 	
Plasma

Specification	 	 	
      The specification for the Plasma set out in Schedule
5 and all applicable legal and regulatory requirements. 	 
	 	Product 	 	 	
 VITIGAM IVIG, an immunoglobulin manufactured from
the Plasma using BPL’s proprietary GAMMAPLEX process. 	 
	 	
Product

Specification	 	 	
The specification for the Product set out in Schedule 3 as varied from time- to-time by agreement between the parties.		 
	 	
Regulatory

Approval	 	 	
All approvals (including without limitation, supplements, amendments, pre- and post-approvals), licenses, registrations or authorisations
by the applicable regulatory authority necessary for manufacturing, distribution and sale in the Territory of the Product.		 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	Royalties 	 	 	
The royalties on the sales of the Products in the Territory as set out in Schedule 2.		 
	 	
Royalty Period		 	 	
The “Royalty Period” is for a period of [ * ] years commencing on [ * ].		 
	 	
Royalty Rate		 	 	
[ * ]% of Net Sales (as defined)		 
	 	Service
    Fee 	 	 	
The fees for the Services as set out in Schedule 2 and any fee for other
services provided by BPL as agreed in writing by the parties.		 
	 	
Services		 	 	
Stability testing, technical and scientific data, technical advice and support to Client in relation to clinical trials of the Product and obtaining the necessary licences for the sale of the Product in the Territory as detailed in Schedule 1.		 
	 	
Term		 	 	
An initial period commencing on the Commencement Date and ending [ * ] years after the date of US Food and Drug Administration (“FDA”) approval of the Product for sale in the United States of
America (the “Initial Period”) and additional renewal periods
each of [ * ] years’ duration (“Renewal
Periods”), unless terminated by either party serving on the other no less than [ * ] months’ written notice of termination (such notice to take effect at the end of the Initial Period or a Renewal Period (as the case may be)) or otherwise terminated in accordance with the terms of this Agreement.		 
	 	
Territory		 	 	
[ * ]		 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

The Schedules

	 	
Schedule 1		 	 	
The Services		 
	 	
Schedule 2		 	 	
The Fees and Payment		 
	 	
Schedule 3		 	 	
Product Specification		 
	 	
Schedule 4		 	 	
Trade Marks		 
	 	
Schedule 5		 	 	
Donor Centres and Plasma Specification		 
	 	
Schedule 6		 	 	
Additional Terms and Conditions		 
	 	
Schedule 7		 	 	
BPL’s Standard Terms and Conditions for Contract Manufacture		 

SIGNED by the parties or their duly authorised representatives on [                                                        ] 20[      ]

Signed by the duly authorised representative of Bio Products Laboratory 

	
Name:		 	 		
Signature:		 
	
Position:		 	 		
Date:		 

Signed by the duly authorised representative of GammaCan Ltd.

	Name: 	 	 	Signature: 	 
	Position: 	 	 	Date: 	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 1 

The Services

	
1     	
All Services be performed in the English language.

	
	 
	
2     	
The Services shall include:

	
	 
	 	
2.1     	
Testing of intermediates and Product in accordance with QC Testing Specifications set out in Schedule 3;

	
	 
	 	
2.2     	
Stability testing in accordance with the Stability Testing Specification set out in Appendix 1 of this Schedule.

	
	 
	 	
2.3     	
Provision of all information normally required for a chemical, manufacturing and control (CMC) section for a U.S. IND and BLA approval (or equivalent) associated with the Product, including but not
limited to viral validation, product characterisation, process validation, assay validation, responding to questions posed by the regulatory authorities, attending regulatory meetings and other related matters. Such provision of information shall,
to the extent applicable, be subject to the terms of the Data Package License attached as Appendix 1 to Schedule 6.

	
	 
	 	
2.4     	
Services not included are those data specifically related to the assay of the active anti melanoma substance

	
	 
	
3     	
Services to also include manufacture of clinical batches and commercial batches of Product according to the terms of this Schedule 1 and the other terms of the Agreement (including, without limitation,
Schedule 7).

	
	 
	 	
3.1     	
Phase I/II Batches

	
	 
	 	 	
3.1.1     	
A first batch of Product manufactured from [ * ] litres of Plasma ready for shipping on or before [ * ].

	
	 
	 	 	
3.1.2     	
An [ * ] second batch of Product manufactured from [ * ] litres of Plasma [ * ] to be ready for shipping on or before [ * ].

	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	 	
3.1.3     	
A [ * ] batch of Product manufactured from [ * ] litres of Plasma ready for shipping on or before [ * ].
	
	 
	 	 	
3.1.4     	
A [ * ] batch of Product manufactured from [ * ] lifters of Plasma ready for shipping on or before [ * ].
	
	 
	 	
3.2     	
Phase III Batches. Batches of Product manufactured from [ * ] litres of
Plasma ready for shipping on or before [ * ].
	
	 
	 	
3.3     	
Additional Clinical Batches. Additional clinical batches to be agreed upon by the parties pursuant to [ * ].
	
	 
	 	
3.4     	
BPL shall [ * ] commence processing of the Phase I/II Batches, the Phase III Batches and any additional clinical
batches within [ * ] days of [ * ]. BPL shall complete manufacture of the Product
within [ * ] days of [ * ]. The Product shall not be warehoused at BPL more than
[ * ] days following such release and shall be shipped to Client or to a Client designated site upon receipt by BPL of applicable shipping instructions from
Client.
	
	 
	 	
3.5     	
BPL shall [ * ] commence processing of any commercial batches of the Product (in quantities described in the Purchase
Order (as defined in Schedule 7)) within [ * ] days of [ * ]. Subject to clause 3.6
of this Schedule 1, BPL shall complete manufacture of the Product within [ * ] days of [ * ]. The Product shall not be warehoused at BPL more than [ * ] following such release and shall be shipped to Client pursuant to clause 4.1 in
Schedule 7 upon receipt by BPL of applicable shipping instructions from Client.
	
	 
	 	
3.6     	
In the event the Product from the processing of commercial batches is not ready for release for sale within [ * ] days
following [ * ], then:
	
	 
	 	 	
3.6.1     	
if the Product is ready for release for sale within the [ * ] days [ * ];
	
	 
	 	 	
3.6.2     	
if the Product is ready for release for sale [ * ] but no later than [ * ], then [ * ]; or
	
	 
	 	 	
3.6.3     	
if the Product is ready for release for sale at any time later than [ * ], then [ * ]:
	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	       	 	 	
(i)     	
[ * ]
	
	 
	 	 	 	
(ii)     	
[ * ]:
	
	 
	 	 	 	 	
(A)     	
[ * ];
	
	 
	 	 	 	 	
(B)     	
[ * ]
	
	 
	 	 	 	 	
(C)     	
[ * ].

	 
	 	3.7     	
      BPL shall not in the [ * ] of commercial production be required to supply Client with [ * ] (although BPL may, at its sole discretion, agree to do so).

	 	 	 	 
	4 	BPL shall render such other services
    as required by any other terms of the Agreement.
	 

 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 1 

Appendix 1 

QC and Stability Testing Specifications 

Product for the U.S will be tested to FDA regulations and requirements 

Product for all other markets will be tested in compliance with local regulatory authorities’ regulations and requirements. 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 2 

Fees and Payment

	
1      		
Manufacturing Fees
	
	 
	 	
1.1     	
The Phase I/II Batches will be processed [ * ] which will be [ * ]. In the event that [ * ]. By way of example, [ * ].
	
	 
	 	
1.2     	
The Phase III batches will be processed [ * ]. In the event that [ * ].
	
	 
	 	
1.3     	
In the event of manufacturing by BPL of Product for commercial sale, [ * ] batches of Plasma will be processed for a
Manufacturing Fee which will be the number of litres of Plasma supplied by Client multiplied by the Net Processing Fee Per Litre, such Net Processing Fee Per Litre calculated as follows:
	
	 
	 	 	
[ * ]

	
	 
	 	 	[Total of 2 Pages Redacted]
	 	 	 
	 	
1.4     	
[ * ].
	
	 
	 	
1.5     	
[ * ].
	
	 
	 	
1.6     	
Subject to a valid invoice from BPL [ * ], Client will pay [ * ]% of such Manufacturing Fee at the time the Plasma is pooled, and shall pay the remaining [ * ]% no later than
[ * ] days following (i) the release for sale of the Product as envisaged in clause 3.5 of Schedule 1 (in the case of commercial sale), or (ii) release for clinical
use of the Product as envisaged in clause 3.4 of Schedule 1 (in the case of clinical use).
	
	 
	 	
1.7     	
Batches for commercial sale set out above shall have a yield of [ * ] grams of IVIG per litre of Plasma.
	
	 
	 	
1.8     	
[ * ].
	
	 
	
2      		
Service Fees
	
	 
	 	
2.1     	
The Service Fee in relation to FDA approval is a total of [ * ] to be paid in the three instalments set out
below:
	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	Instalment      	 	 	Date for Payment      
	 	
[ * ]		 	 	
[ * ]	
	 	
[ * ]		 	 	
[ * ]	
	 	
[ * ]		 	 	
[ * ]	

	
2.2     	
The Service Fee in relation to approval in the European Union (“EU”) is a total of [ * ] to be paid in the three instalments set out below

	
	 

	 	 Instalment 	 	 	Date
    for Payment 
	 	[
          * ] 	 	 	[
          * ] 
	 	[
          * ] 	 	 	[
          * ] 
	 	[ * ] 	 	 	[ * ] 

	 	
2.3     	
In the event Client elects to seek Regulatory Approval outside of the United States of America and the EU, [ * ].

	
	 
	
3      		
Royalties

	
	 
	 	
3.1     	
During the Term, Client shall pay to BPL the Royalty Rate for the Royalty Period in respect of Net Sales (as defined under ‘Key Terms’) of the Product in the Territory within [ * ] days of the end of each quarter in respect of Net Sales during the previous quarter.

	
	 
	 	
3.2     	
When royalties are due to be paid under this Agreement, Client shall prepare and submit to BPL a statement in writing showing the amount of the turnover in the Products in the Territory during the
relevant quarter, the calculation of the amount of royalties due and payable and the amount of any applicable tax on the royalty to be deducted.

	
	 
	 	
3.3     	
Client shall keep proper records
    and books of account showing the turnover in the Products in the Territory
    which shall be open to inspection and audit by BPL or its duly appointed
    agent or  representative who shall be entitled to take copies of or extracts
    from them. In the event that any such inspection or audit shall reveal any shortfall in the royalties
    paid from those payable under this Agreement, Client shall [ * ].

	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 2

Appendix 1

[ * ]

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 2

Appendix 2

[ * ]

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 3

Product Specification

See Appendix 1 of this Schedule 3 for Product Specification. 

This Product Specification is subject to Regulatory Approval, which may change from time-to-time and may further be subject to change from time-to-time by written agreement by both parties. 

 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 3 

Appendix 1: Vitigam Product Specification

[ * ] 

[Total of 3 Pages Redacted]

 

 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 4 

Trade Marks

GammaCan word mark 

GammaCan logo as set forth on Appendix 1 of this Schedule 4 

Vitigam word mark 

Such other trademarks as designated by Client from time to time.

 

 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 4

Appendix 1

      

  

    

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 5 

Donor Centres and Plasma Specification

	1	Donor Centres
	 	 
	 	Client to supply all documentation
        required by the appropriate regulatory authorities pertaining to the
    donor centres. 
	 	 
	2	Plasma Specification
	 	 	 
	 	2.1	 For the U. S. market: in accordance and
    fully compliant with FDA rules and regulations. 
	 	 	 
	 	2.2	 For markets outside of the U. S. , in
        accordance and fully compliant with rules and regulations as set forth
    by relevant regulatory authorities. 
	 	 	 
	 	2.3	 Specifications set forth in Appendix
        1 to Schedule 5. These specifications may be subject to change from time-to-time
    by written agreement by both parties. 

 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 5 

Appendix 1 – Specifications for U.S. Plasma

 

 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

 

	  
	SPECIFICATION
      FOR US PLASMA 
     
	 
	 

	
Written By:		 	 		
Date:		 
	 	

	
Agreed for BPL By:		  	 		
Date:		 
		 Technical Director	 		 	
	 	
	
Agreed for BPL By:		  	 		
Date:		  

		Production Manager	 		 	
	 	
	
Authorised BPL By:		  
	 		
Date:		  

	 	Quality
    Assurance 	 		 	

	
Agreed for GammaCan By:		  
	 	
Date:		  

	
Authorised for GammaCan By:		  
	 	
Date:		  

	
Effective date:		  
	 

This specification is a controlled document. Copies will be made only from the master in accordance with the approved procedure. Copies will be returned and accounted for on issue of a revision. Copies will be numbered
on issue. Copies for Suppliers will be internally controlled from their retained signed copy. 

This copy is number..........................

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

[ * ] 

[Total of 13 Pages Redacted]

 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 6 

Additional Terms and Conditions

	
1     	
In the event of any conflict, these Additional Terms and Conditions shall have priority over the other terms of this Agreement.

	
	 
	
2     	
Data Package Licence

	
	 
	 	
2.1     	
BPL hereby grants to Client for the Term a licence to use the GAMMAPLEX Data in accordance with the terms set out in Appendix 1 to this Schedule.

	
	 
	
3     	
By-Products

	
	 
	 	
3.1     	
Save for [ * ], [ * ] shall own, at
no cost to [ * ], all of the By-Products.

	
	 
	 	
3.2     	
[ * ].

	
	 
	
4     	
Regulatory Approvals

	
	 
	 	
4.1     	
BPL acknowledges that the Regulatory Approvals of the Product shall be in the name of Client.

	
	 
	 	
4.2     	
BPL will maintain and retain true and accurate books, records, test and laboratory data, reports and all other information relating to manufacturing under this Agreement, including all applicable laws
and regulations (including cGMPs) as well as records of work performed. BPL will maintain all such information only in separate forms, notebooks and records to the extent possible (not commingled with other information) and will maintain all such
information for a period of at least [ * ] years from the relevant Product expiration date or longer if required under applicable laws and regulations (including
cGMPs).

	
	 
	
5     	
Insurance

	
	 
	 	
Each of Client and BPL shall [ * ].

	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	
6     	
Product Recall and Returns

	
	 
	 	
If Client initiates a product recall, or returns any Products to BPL, [ * ], then [ * ], BPL shall [ * ] to Client [ * ].

	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 6 

Appendix 1 

Data Package Licence

BACKGROUND

	
A.      		
Client is to have access to all
    data required for any Regulatory Approvals, for the purpose of securing authorisation
    to manufacture the Product using the manufacturing process of BPL including,
    without  limitation, its “GAMMAPLEX” process (collectively, the “GAMMAPLEX Data”).
	
	 
	
B.      		
Client would like to secure equivalent authorisation for the GAMMAPLEX Data in order to market, distribute and sell the Product in the Territory.
	
	 
	
C.      		
To enable Client to secure such authorisations, BPL has agreed to grant a licence to Client to use the GAMMAPLEX Data in connection with its U.S. regulatory approvals, EU and other regulatory approvals,
and in connection with the commercial sale of Product.
	
	 

OPERATIVE PROVISIONS

	
1.      		
Definitions and interpretation

	
	 
	 	
1.1     	
In this Appendix including the ‘Background’ recital, unless the context otherwise requires:

	
	 
	 	 	
“Confidentiality Provisions” means clause 9 of Schedule 7 to this Agreement;

	
	 
	 	 	
“Purpose” means the purpose of securing regulatory authorisation to (i) manufacture the Product using the
GAMMAPLEX Data, and (ii) market, distribute and sell in the Territory, Product manufactured by BPL in accordance with this Agreement;

	
	 
	
2      		
Grant

	
	 
	 	
2.1     	
BPL hereby grants to Client a fully paid, royalty free, worldwide, non-exclusive licence to use the GAMMAPLEX Data for the Purpose.

	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	
2.2     	
Client shall not grant sub-licences under this Appendix, it being understood that the provisions of this clause 2.2 will not derogate from clause 3.3 of Schedule 7.

	
	 
	 	
2.3     	
No further right or licence is granted by BPL to Client by this Appendix, save as expressly set out in this paragraph 2.

	
	 
	 	
2.4     	
Client undertakes, during the Term, not itself to exploit the GAMMAPLEX Data in the Territory other than for the Purpose.

	
	 
	
3.      		
Provision of know-how

	
	 
	 	
3.1     	
BPL shall make available to Client such know-how relating to the manufacture of the Product as is necessary for the Purpose.

	
	 
	 	
3.2     	
The know-how supplied by BPL under paragraph 3 shall be used by Client only for the Purpose and shall be subject to the Confidentiality Provisions.

	
	 
	
4.      		
Improvements

	
	 
	 	
4.1     	
If BPL identifies a Manufacturing Improvement at any time during the Term, [ * ].

	
	 
	 	
4.2     	
Any Manufacturing Improvement implemented at BPL to the GAMMAPLEX Data shall be made [ * ].

	
	 
	 	
4.3     	
Information provided by BPL to Client under paragraphs 4.1 and 4.2 shall be subject to the Confidentiality Provisions.

	
	 
	
5      		
Compliance

	
	 
	 	
5.1     	
Client shall supply BPL with copies of all data and correspondence provided to, or received from, the competent authorities in the Territory for purposes of obtaining authorisation to market the Product
in the Territory.

	
	 
	 	
5.2     	
Client and BPL shall comply with all legal requirements from time to time in force in the Territory relating to the storage and supply of human blood products, the use of equipment (including in vitro
diagnostic devices), manufacture, the storage, labelling, marketing, distribution and sale of the Products.

	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	
5.3     	
BPL shall use all reasonable efforts to cooperate and assist Client in obtaining and maintaining all necessary approvals (including without limitation, supplements, amendments, pre- and post-
approvals), licenses, registrations or authorisations of any U.S. FDA or EU national, supra-national (e.g., the European Commission or the Council of the European Union), regional, state or local regulatory agency, department, bureau, commission,
council or other governmental entity, necessary for the manufacture, distribution, use or sale of the Product in any regulatory jurisdiction within the Territory from all regulatory authorities necessary for commercial sale.

	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

Schedule 7 

Bio Products Laboratory - Standard Terms and Conditions for Contract Manufacture

	1      	
      Definitions

	 
	 	1.1	
 In this Agreement, the following
    words shall have the following meanings:

	
	 
	 	 	
“Claims” means all demands, claims and liability (whether criminal or civil, in contract, tort or otherwise
for losses, damages, legal costs and other expenses of any nature whatsoever and all reasonable and accountable costs and expenses (including, without limitation, legal costs) incurred in connection therewith.

	
	 
	 	 	
“BPL Know-how“ means all industrial, commercial and technical records and information concerning BPL’s
proprietary GAMMAPLEX process.

	
	 
	 	 	
“Client Know-how” means all industrial, commercial and technical records and information concerning the
Product belonging to Client, including, without limitation, a test for the potency of the Product for the purposes of process monitoring and lot release.

	
	 
	 	 	
“BPL Intellectual Property” means the BPL Know-how and other intellectual property including, without
limitation, copyright, database rights, design rights, patents and patent applications, and rights in respect of BPL Confidential Information.

	
	 
	 	 	
“Client Intellectual Property” means Client Know-how, Trade Marks and other intellectual property including,
without limitation, copyright, database rights, design rights, patents and patent applications, and rights in respect of Client Confidential Information.

	
	 
	 	 	
“Facility” means the location where the Product is to be manufactured by BPL.

	
	 
	 	 	
“Representatives” means the employees, agents and representatives of the applicable party
hereunder.

	
	 
	 	 	
“Schedule” means a schedule to this Agreement.

	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	
“Trade Marks” means the registered and unregistered trade marks which are set out in Schedule 4.

	
	 
	
2      		
Provision of Know-how, Equipment and Plasma
	
	 
	 	
2.1     	
Effective with the Commencement Date Client shall disclose to BPL such Client Know-how and BPL shall disclose to Client such BPL Know-how that is necessary to manufacture the Product in accordance with
the Product Specification.
	
	 
	 	
2.2     	
The provision and use of the BPL Know-how and Client Know-how shall be subject to the confidentiality provisions of clause 9 of this Schedule.
	
	 
	 	
2.3     	
The Parties shall from time to time consult with regard to the use of the BPL Know- how and Client Know-how, as applicable, and other technical aspects to enable BPL to manufacture the Product in
accordance with the Product Specification.
	
	 
	 	
2.4     	
In addition, BPL may request from time to time reasonable assistance from Client regarding the use of Client Know-how and other technical aspects to enable BPL to manufacture the Product in accordance
with the Product Specification.
	
	 
	 	
2.5     	
During the provision of such assistance at the Facility or any other location of BPL:
	
	 
	 	 	
2.5.1     	
the Representatives of Client shall comply with BPL’s policies on security, safety and other relevant matters;
	
	 
	 	 	
2.5.2     	
Client shall indemnify BPL against any damage to the property of BPL or personal injury, which is caused by the negligent act or omission of the Representatives of Client on the premises of BPL;
and
	
	 
	 	 	
2.5.3     	
BPL shall indemnify Client against any damage to the property of Client or personal injury, which is caused by the negligent act or omission of BPL.
	
	 
	 	
2.6     	
Client shall supply Client Materials
    to BPL by causing their delivery to [ * ] If [ * ], then the
    parties shall agree upon a mutually acceptable place for delivery of Client
    Materials. [ * ] shall be responsible for clearing Client Materials
    for export and import. Risk of damage
    to or loss of Client Materials shall pass to BPL [ * ].
	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	
2.7     	
As soon as reasonably practicable after the arrival of Client Materials at the Facility, BPL shall inspect such Client Materials to ensure they are in compliance with the Plasma Specification. Subject
to any regulatory requirements, BPL shall not process any Plasma prior to [ * ] days from collection at the Donor Centre. In the event that such Client Materials fail
to comply with the Plasma Specification, BPL shall notify Client in writing of the reasons for the same and shall, [ * ].

	
	 
	
3      		
Manufacture of the Product

	
	 
	 	
3.1     	
Client shall not, for the duration of the Term, [ * ].

	
	 
	 	
3.2     	
Product Supply Forecasts: In the event Client wishes to commence commercial production of the Product, Client shall provide BPL with a [ * ] rolling forecast of Client’s estimated production and supply needs for Product, expressed as litres for each calendar month (the “Production Forecast”), initially no less than [ * ] months in advance and subsequently no less than [ * ] months in advance. Client shall provide an
updated Production Forecast each [ * ] months. The first [ * ] months of each
Production Forecast shall be binding on Client and shall be accompanied by a binding purchase order in respect of an amount which shall vary by no more or less than [ * ] (a “Purchase Order”).

	
	 
	 	
3.3     	
BPL shall confirm whether it is able to fulfil Client’s requirements set out in each Production Forecast within [ * ] days of receipt of the same. In the event BPL cannot supply Client’s forecasted requirements, [ * ].

	
	 
	 	
3.4     	
[ * ].

	
	 
	 	
3.5     	
Client acknowledges that BPL’s ability to manufacture and supply the Product at times and quantities as may be agreed from time to time depends on the availability to BPL of sufficient quantities
of Plasma to permit manufacture of the Product. Client is also aware and acknowledges that BPL has subsisting obligations to give priority of manufacture of plasma derived products to the Authority for the supply of the United Kingdom and may by
reason of national or international emergency or at the direction of the Authority be required to give priority of manufacture and supply of plasma derived products to the Authority or third parties. If BPL is required to give such priority, then
[ * ].

	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	
4      		
Delivery, inspection and testing
	
	 
	 	
4.1     	
Subject to clause 4.2, BPL shall package the Product suitable for air freight and shall deliver the Product [ * ].
	
	 
	 	
4.2     	
The property in the Plasma, the Product (or in any quantity of Product) and any work- in-progress shall remain [ * ].
	
	 
	 	
4.3     	
Prior to release for sale or clinical use of the Product (or any quantity of Product), BPL shall inspect and test the Product (or the quantity of Product) to ensure that it is in accordance with the
Product Specification and any other requirements set forth herein. If requested by Client, BPL shall supply a copy of the documentation relating to the inspection and testing. At the conclusion of each stage of inspection and testing, BPL shall
certify that the Product (or quantity of Products) has been manufactured in accordance with the Product Specification and any other requirements set forth herein.
	
	 
	 	
4.4     	
If reasonably requested by Client,
    BPL shall permit the Representatives of Client to inspect and test the Product
    at any stage during the process of manufacturing, packing and delivery. BPL
    shall  provide such facilities and access to resources as Client may reasonably
    require to carry out such inspection and testing. If the Representatives
    of Client after carrying out such inspection and testing conclude that the
    Product that is tested and  inspected is not being manufactured in accordance
    with the Product Specification or otherwise in accordance with this Agreement
    then [ * ].
	
	 
	 	
4.5     	
Client or its distributor shall inspect all shipments of Product received from BPL for [ * ] within [ * ] days of [ * ]. If any portion of the Product fails to conform with this Agreement
[ * ], then [ * ].
	
	 
	 	
4.6     	
BPL shall be responsible for, to the extent required by this Agreement:
	
	 
	 	 	
4.6.1     	
receipt of Client Material in accordance with clause 2.6 and storage prior to manufacturing;
	
	 
	 	 	
4.6.2     	
purifying and processing the Plasma to manufacture Product;
	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	 	
4.6.3     	
filling, finishing and providing country specific labelling and packaging of Product;

	
	 
	 	 	
4.6.4     	
quality assurance and release testing;

	
	 
	 	 	
4.6.5     	
storage of Product prior to shipment; and

	
	 
	 	 	
4.6.6     	
preparation of all necessary export documentation.

	
	 
	
5      		
Fees, Royalties and Payment

	
	 
	 	
5.1     	
Client shall pay the Manufacturing Fee, the Service Fee and the Royalties in accordance with Schedule 2.

	
	 
	 	
5.2     	
All amounts stated are exclusive of VAT and/or any other applicable taxes or levy, which shall be paid in addition by Client at the rate in force at the date any payment is required from
Client.

	
	 
	 	
5.3     	
If payment of any sum due under this Agreement is not received by any due date specified for that sum, BPL may charge interest on the outstanding amount at the rate of [ * ]% per annum above the base lending rate of Bank of England, accruing daily.

	
	 
	 	
5.4     	
Client shall not be entitled to assert any credit set-off or counterclaim against BPL in order to justify withholding payment of any amount due under this Agreement in whole or in part.

	
	 
	 	
5.5     	
To the extent that any sums due to BPL are unpaid and accrued at the date of termination or expiration of this Agreement (including any royalties under clause 11.4), the provisions of this Clause 5
shall remain in effect notwithstanding termination or expiry of this Agreement until the payment of all such sums due by Client.

	
	 
	
6      		
Standard of manufacture of the Products

	
	 
	 	
6.1     	
BPL warrants that it has the necessary skills, experience, expertise and capabilities to manufacture the Products in accordance with the Product Specification;

	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	
6.2     	
Client represents, warrants and covenants that the manufacture, processing, testing distribution, transport, storage, disposal and other handling of the Plasma by Client until delivery to BPL shall
conform to the Plasma Specification. Client shall deliver to BPL any certificate or other documentation as reasonably required by BPL specifying the results of its testing to show conformance with the Plasma Specifications.

	
	 
	 	
6.3     	
BPL represents, warrants and covenants that [ * ] shall (i) [ * ]
(ii) [ * ] (iii) [ * ] (iv) [ * ] (v) [ * ].

	
	 
	
7      		
The Services

	
	 
	 	
7.1     	
With effect from the Commencement Date, BPL shall provide the Services in accordance with the terms of this Agreement.

	
	 
	 	
7.2     	
BPL shall provide the Services with reasonable skill and care.

	
	 
	
8      		
Intellectual Property

	
	 
	 	
8.1     	
All BPL Intellectual Property owned or licensed by BPL at the date of this Agreement shall remain so owned or licensed save as expressly set out in this Agreement. All Client Intellectual Property owned
or licensed by Client at the date of this Agreement shall remain so owned or licensed save as expressly set out in this Agreement.

	
	 
	 	
8.2     	
Client grants an exclusive licence to BPL in the Territory to use Client Know-how for the Term (and Client Intellectual Property necessary for the use of Client Know-how under this Agreement) and to
apply for the Term the Trade Marks to the Product.

	
	 
	 	
8.3     	
The licences granted under clause 8.2 are only to allow BPL to exercise its rights and perform its obligations under this Agreement.

	
	 
	 	
8.4     	
Except for the licences granted under clause 8.2, no other licence is granted by Client to BPL.

	
	 
	 	
8.5     	
BPL shall use the Trade Marks only as specified in the Product Specification and only in relation to the Product and in accordance Client’s trademark usage guidelines as may be notified to BPL from
time to time. Client to pre-approve in writing all labelling language and layout. Without derogating from the aforesaid, BPL

	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	 	
acknowledges that all labelling language and layout is subject to Regulatory Approval.

	
	 
	 	
8.6     	
All documentation, specifications and artwork provided by Client to BPL for use on or in relation to the Product and the packaging for the Product (and the Intellectual Property in it) are, and shall
remain, the property of Client.
	
	 
	 	
8.7     	
As between BPL and Client, all improvements to manufacturing processes, patentable or otherwise (“Manufacturing Improvements”), shall be owned exclusively by BPL regardless who discovers or
invents such Manufacturing Improvements. To the extent such Manufacturing Improvements are discovered or invented by Client or its Representatives, Client hereby irrevocably assigns, sets over and transfers to BPL such Manufacturing Improvements by
way of current assignment of future rights and all right, title and interest therein including, without limitation, all intellectual property rights, free and clear of all liens or encumbrances and any rights, title or interests of third parties.
Client agrees that Client and Client’s Representatives shall, during and after the Term, cooperate fully in obtaining patent and other proprietary protection for Manufacturing Improvements all in the name of BPL (but at BPL’s expense), and
without limitation, shall execute all requested applications, assignments and other documents in furtherance of obtaining such protection or registration and confirming full ownership by BPL of such Manufacturing Improvements. Client hereby
designates BPL as Client’s agent, and grants BPL a power of attorney with full substitution, which power of attorney shall be deemed coupled with an interest, for the purposes of effecting the foregoing assignments from Client to BPL. In
relation only to the Product, Client shall have an irrevocable, fully paid, royalty-free, worldwide, non-exclusive licence to use, including to sub-license, the Manufacturing Improvements.
	
	 
	 	
8.8     	
As between BPL and Client, all improvements to the Product or the Product format, patentable or otherwise (“Product Improvements”), shall be owned exclusively by Client regardless who
discovers or invents such Product Improvements. To the extent such Product Improvements are discovered or invented by BPL or its Representatives, BPL hereby irrevocably assigns, sets over and transfers to Client such Product Improvements by way of
current assignment of future rights and all right, title and interest including, without limitation, all intellectual property rights, free
	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	
 

		and clear of all liens or encumbrances and
    any rights, title or interests of third parties. BPL agrees that BPL and
    BPL’s Representatives shall, during and after the Term, cooperate fully
    in obtaining patent and other proprietary protection for Product Improvements
    all in the name of Client (but at Client’s expense), and without limitation,
    shall execute all requested applications, assignments and other documents
    in furtherance of obtaining such protection or registration and confirming
    full ownership by Client of such Product Improvements. BPL hereby designates
    Client as BPL’s agent, and grants Client a power of attorney with full
    substitution, which power of attorney shall be deemed coupled with an interest,
    for the purposes of effecting the foregoing assignments from BPL to Client.
    BPL shall have a royalty-free non- exclusive licence to use the Product Improvements
    for the purposes of this Agreement.
	 
	
9      		
Confidentiality
	
	 
	 	
9.1     	
Each Party (the “Receiving Party”) undertakes:
	
	 
	 	 	
9.1.1     	
to maintain as secret and confidential all BPL Know-how and Client Know-how, as applicable, and other technical or commercial information obtained directly or indirectly from the other Party (“the
Disclosing Party”) in the course of or in anticipation of this Agreement (collectively, the “Confidential Information”) and to respect the Disclosing Party's rights therein;
	
	 
	 	 	
9.1.2     	
to use the same exclusively for the purposes of this Agreement; and
	
	 
	 	 	
9.1.3     	
to disclose the same only to those of its employees, contractors, professional advisors and sub-licensees pursuant to this Agreement (if any) to whom and to the extent that such disclosure is reasonably
necessary for the purposes of this Agreement.
	
	 
	 	
9.2     	
The provisions of clause 9.1 shall not apply to Confidential Information which the Receiving Party can demonstrate by reasonable written evidence:
	
	 
	 	 	
9.2.1     	
was, prior to its receipt by the Receiving Party from the Disclosing Party, in the possession of the Receiving Party and at its free disposal; or
	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	 	
9.2.2     	
is subsequently disclosed to the Receiving Party without any obligations of confidence by a third party who has not derived it directly or indirectly from the Disclosing Party; or
	
	 
	 	 	
9.2.3     	
is or becomes generally available to the public through no act or default of the Receiving Party or its agents, employees, affiliates or sub-licensees; or
	
	 
	 	 	
9.2.4     	
is required to be disclosed by the Receiving Party to the courts of any competent jurisdiction, or to any government regulatory agency or financial authority, provided that the Receiving Party
shall:
	
	 
	 	 	 	
(a)     	
inform the Disclosing Party as soon as is reasonably practicable, and
	
	 
	 	 	 	
(b)     	
at the Disclosing Party's request seek to persuade the court, agency or authority to have the information treated in a confidential manner, where this is possible under the court, agency or authority's
procedures.
	
	 
	 	
9.3     	
The Receiving Party shall procure that all of its employees, contractors and sub-licensees pursuant to this Agreement (if any) who have access to the Confidential Information shall be made aware of
these obligations and shall have entered into written undertakings of confidentiality with the Receiving Party at least as restrictive as clauses 9.1 and 9.2 and which apply to the Confidential Information.
	
	 
	 	
9.4     	
Notwithstanding anything contained herein, the Receiving Party may disclose such Confidential Information to government or other regulatory authorities to the extent that such disclosure is reasonably
necessary to obtain and maintain patents and Regulatory Approvals.
	
	 
	 	
9.5     	
BPL acknowledges that Client is a publicly traded company. As such BPL agrees not to use any Confidential Information in connection with the purchase of the sale of securities of Client in violation of
Unites States securities laws.
	
	 
	 	
9.6     	
The provisions of this clause 9 shall remain in effect, notwithstanding the termination or expiry of this Agreement for any reason.
	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	
10      		
Liability and Indemnities

	
	 
	 	
10.1     	
Nothing in this Agreement shall exclude or restrict the liability of either party to the other for (i) death or personal injury resulting from negligence, or for fraudulent misrepresentation or (ii) in
any other circumstances where liability may not be so limited under any applicable law.

	
	 
	 	
10.2     	

[ * ], neither party shall be liable to the other whether in contract, tort, negligence, breach of statutory duty or otherwise for loss of profit, revenue,
use, anticipated savings, goodwill, reputation or opportunity, financial or other economic loss, in each case whether direct or indirect, or any indirect or consequential loss or damage, costs or expenses whatsoever or howsoever arising out of or in
connection with this Agreement.

	
	 
	 	
10.3     	
[ * ]:

	
	 
	 	 	
10.3.1     	
[ * ]

	
	 
	 	 	
10.3.2     	
[ * ]

	
	 
	 	 	
10.3.3     	
[ * ].

	
	 
	 	
10.4     	
[ * ]:

	
	 
	 	 	
10.4.1     	
[ * ]

	
	 
	 	 	
10.4.2     	
[ * ]

	
	 
	 	 	
10.4.3     	
[ * ].

	
	 
	 	
10.5     	
Without derogating from clause 1.5 of Schedule 2, for the purpose of clauses 10.2, 10.3 and 10.4, any number of acts or omissions whether successive or concurrent which together result in or contribute
to substantially the same loss or damage shall be treated as one act or omission.

	
	 
	 	
10.6     	
Except as set out in this Agreement, all warranties, conditions, terms and undertakings, express or implied, whether by statute, common law, custom, trade usage, course of dealings or otherwise
(including without limitation as to quality,

	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	 	
performance or fitness or suitability for purpose) in respect of any materials, products or services to be provided under this Agreement are excluded to the fullest extent permitted by law.

	
	 
	 	
10.7     	
BPL agrees to defend, indemnify and hold Client, its affiliates and their respective directors, officers, shareholders, agents, successors and permitted assigns harmless from and against all third party
Claims:
	
	 
	 	 	
10.7.1     	
[ * ]
	
	 
	 	 	
10.7.2     	
[ * ]
	
	 
	 	 	
[ * ]

	
	 
	 	
10.8     	
Client agrees to defend, indemnify and hold BPL, its affiliates and their respective directors, officers, shareholders, agents, successors and permitted assigns harmless from and against all third party
Claims:
	
	 
	 	 	
10.8.1     	
[ * ]
	
	 
	 	 	
10.8.2     	
[ * ]
	
	 
	 	 	
10.8.3     	
[ * ]
	
	 
	 	 	
[ * ]

	
	 
	 	
10.9     	
A party (the “Indemnitee”) that intends to claim indemnification under this clause shall promptly notify the other party (the “Indemnitor”) of any liability or action in respect of
which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have the right to participate in and to assume the defence thereof with counsel selected by the Indemnitor and approved by Indemnitee; provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitor if Indemnitee reasonably concludes that there
is a conflict of interest between the Indemnitor and Indemnitee in the conduct of any such defence. The indemnity obligations under this clause shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the
consent of the Indemnitor, which consent shall not be withheld unreasonably. The failure to deliver notice to the Indemnitor within a reasonable time after the
	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	 	commencement of any such action
      shall relieve such Indemnitor of liability to the Indemnitee under this
      clause to the extent such failure is prejudicial to its ability to defend
      such action, but the omission so to deliver notice to the Indemnitor will
      not relieve it of any liability that it may have to the Indemnitee otherwise
      than under this clause. The Indemnitee and its Representatives shall cooperate
      fully with the Indemnitor and its legal representatives in the investigation
    of any Claim covered by this indemnification. 
	 	 
	
11      		
Duration and termination
	
	 
	 	
11.1     	
This Agreement shall come into effect on the Commencement Date and, unless terminated earlier in accordance with this clause 11, shall continue in force for the Term.
	
	 
	 	
11.2     	
Without prejudice to any other right or remedy, either Party may terminate this Agreement at any time by notice in writing to the other Party (the “Other
Party”), such notice to take effect as specified in the notice:
	
	 
	 	 	
11.2.1     	
if the Other Party is in breach of this Agreement and the breach is not remedied within [ * ] days of the Other Party
receiving notice specifying the breach and requiring its remedy; or
	
	 
	 	 	
11.2.2     	
if the Other Party becomes insolvent, or if an order is made or a resolution is passed for the winding up of the Other Party, or if an administrator, administrative receiver or receiver is appointed in
respect of the whole or any part of the Other Party's assets or business, or if the Other Party makes any composition with its creditors or takes or suffers any similar or analogous action in consequence of debt.
	
	 
	 	
11.3     	
On the termination or expiry of this Agreement for any reason BPL shall:
	
	 
	 	 	
11.3.1     	
Forthwith complete all work in progress under this Agreement and deliver to Client all finished Product (and Client shall pay the Manufacturing Fee for such Services calculated in accordance with this
Agreement);
	
	 
	 	 	
11.3.2     	
cease use of Client Know-how and Client Intellectual Property save as necessary to comply with clause 11.3.1 above;
	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	 	
11.3.3     	
return to Client all Know-how supplied by Client to BPL in documentary form including any copies made;
	
	 
	 	 	
11.3.4     	
no longer use or apply any of the Trade Marks;
	
	 
	 	 	
11.3.5     	
consent to the cancellation of any formal licence granted to it, or of any record of it in any register, in respect of Client Intellectual Property or the Trade Marks.
	
	 	 	 	 
	 	11.4     	On the termination or expiry
        of this Agreement for any reason Client shall have the right to dispose
        of all stocks of the Product in its possession and all Product in the
        course of manufacture at the date of termination, provided that any royalty
        payable under the provisions of this Agreement (as if such stocks were
        supplied at the date of termination) is paid to BPL in accordance with
    the terms of this Agreement.

	 	 	 	 
	 	11.5     	Termination or expiry of
        this Agreement shall not affect the operation of those clauses expressed
        to survive such termination or expiry which shall include the following:
        clauses 2.5.2, 2.5.3, 3.5, 4.3, 6.1, 6.2, 6.3, 8.1, 8.6, 8.7, 8,8, 9,
        10, 11.3, 11.4 of this Schedule 7, clauses 1.5 and 1.7 of Schedule 2
    and clauses 4, 5 and 6 of Schedule 6.

	 
	
12      		
General
	
	 	 	 	 
	 	
12.1     	
Each party hereby represents and warrants to the other party that (a) the person executing this Agreement is authorized to execute this Agreement; (b) this Agreement is legal and valid and the
obligations binding upon such party are enforceable by their terms; and (c) the execution, delivery and performance of this Agreement does not violate any law or regulation of any court, governmental body or administrative or other agency having
jurisdiction over it.
	
	 
	 	
12.2     	
Neither Party shall have any liability or be deemed to be in breach of this Agreement for any delays or failures in performance of this Agreement which result from circumstances beyond the reasonable
control of that Party, including without limitation labour disputes involving that Party. The Party affected by such circumstances shall promptly notify the other Party in writing when such circumstances cause a delay or failure in performance and
when they cease to do so. [ * ]
	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	
12.3     	
This Agreement may only be amended in writing signed by duly authorised representatives of the Parties.
	
	 
	 	 	
12.3.1     	
[ * ], neither Party shall assign, mortgage, charge or otherwise transfer any rights or obligations under this Agreement without the prior written consent of
the other Party.
	
	 
	 	 	
12.3.2     	
[ * ].
	
	 
	 	 	
12.3.3     	
Each Party may assign all its rights and obligations under this Agreement pursuant to a sale of stock or a sale of all or substantially all of each parties’ assets, it being understood that any
such assignment is to an assignee that is qualified to carry out the provisions of this Agreement.
	
	 
	 	
12.4     	
No failure or delay on the part of either Party to exercise any right or remedy under this Agreement shall be construed or operate as a waiver thereof, nor shall any single or partial exercise of any
right or remedy preclude the further exercise of such right or remedy.
	
	 
	 	
12.5     	
If any provision or part of this Agreement is held to be invalid, amendments to this Agreement may be made by the addition or deletion of wording as appropriate to remove the invalid part or provision
but otherwise retain the provision and the other provisions of this Agreement to the maximum extent permissible under applicable law.
	
	 
	 	
12.6     	
Neither Party shall act or describe itself as the agent of the other, nor shall it make or represent that it has authority to make any commitments on the other's behalf.
	
	 
	 	
12.7     	
In this Agreement:
	
	 
	 	 	
12.7.1     	
the headings are used for convenience only and shall not affect its interpretation;
	
	 
	 	 	
12.7.2     	
references to persons shall include incorporated and unincorporated persons; references to the singular include the plural and vice versa; and references to the masculine include the feminine;
	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	 	 	
 12.7.3     
		references to the grant of 'exclusive'
        rights shall mean that the person granting the rights shall neither grant
    the same rights (in the same field and territory) to any other person.
	 
	 	
12.8     	
Each Party agrees to execute, acknowledge and deliver such further instruments, and do all further similar acts, as may be reasonably necessary or appropriate to carry out the purposes and intent of
this Agreement.
	
	 
	 	
12.9     	
Neither Party shall make any press or other public announcement concerning any aspect of this Agreement, or make any use of the name of the other Party in connection with or in consequence of this
Agreement, without the prior written consent of the other Party, not to be unreasonably withheld other than disclosure required to the U.S. Securities and Exchange Commission and other similar U.S. and U.K. agencies and to the FDA and any other
similar regulatory authorities.
	
	 
	 	
12.10     	
This Agreement sets out the entire agreement between the Parties relating to its subject matter and supersedes all prior oral or written agreements, arrangements or understandings between them relating
to such subject matter including, without limitation, that certain undated Letter of Intent executed by the parties and that certain Confidentiality Agreement between the parties dated March 21, 2006. The Parties acknowledge that they are not
relying on any representation, agreement, term or condition which is not set out in this Agreement.
	
	 
	 	
12.11     	
This Agreement does not create any right enforceable by any person who is not a party to it under The Contracts (Rights of Third Parties) Act 1999.
	
	 
	
13      		
Notices
	
	 
	 	
13.1     	
Notices sent as above shall be deemed to have been received three working days after the day of posting (in the case of inland first class mail), or seven working days after the date of posting (in the
case of air mail), or on the next working day after transmission (in the case of fax messages, but only if a transmission report is generated by the sender’s fax machine recording a message from the recipient’s fax machine, confirming that
the fax was sent to the number indicated above and confirming that all pages were successfully transmitted).
	
	 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

	
14      		
Law and jurisdiction

	
	 
	 	
14.1     	
The validity, construction and performance of this Agreement shall be governed by English law.

	
	 
	 	
14.2     	
Any dispute arising out of or in connection with this Agreement, including any question regarding its existence, validity or termination, or the legal relationships established by this Agreement, shall
be referred to and finally resolved by arbitration under the Rules of the London Court of International Arbitration, which Rules are deemed to be incorporated by reference into this clause.

	
	 

************************* 

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY BLANK]

 

 

* Portions of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}]]